Changes in plasma levels of FSH, LH and testosterone during anti-androgenic hormone therapy for patients with prostatic cancer.
D000328:Adult; D000368:Aged; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003907:Dexamethasone / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D006589:Hexestrol / Q000627:therapeutic use*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D013737:Testis / Q000601:surgery; D013739:Testosterone / Q000097:blood* / Q000378:metabolism; D013997:Time Factors; D014555:Urination Disorders / Q000188:drug therapy
D006063:Chorionic Gonadotropin; D006589:Hexestrol; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004054:Diethylstilbestrol; D003907:Dexamethasone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone